FDA Lifts Clinical Hold Form Filana Therapeutics' Investigational New Drug Application To Initiate Planned Phase 2a Trial In Participants With Tuberous Sclerosis Complex-Related Epilepsy
Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing simufilam for the treatment of Tuberous Sclerosis Complex
Share
Why It Matters
Filana got permission to test a new medicine for a rare disease. This means the company can move forward with its plan to help patients.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.